MicroVue sC5b-9 Plus ELISA在Dynex DS2平台上的验证与性能
该研究评估了Quidel MicroVue sC5b-9 Plus酶免疫分析法在Dynex DS2平台上的分析性能与临床准确性,用于筛查造血干细胞移植相关血栓性微血管病(TA-TMA)高风险患者。结果显示批内和日间精密度变异小于13%,线性范围80-1600 ng/mL,溶血干扰至800 mg/dL无影响,监测sC5b-9水平变化2-3倍对TA-TMA患者监测有显著性意义。
要点
- sC5b-9 Plus ELISA在Dynex DS2平台上精密度良好,变异小于13%
- 线性范围80-1600 ng/mL,溶血至800 mg/dL无干扰
- sC5b-9水平变化2-3倍对TA-TMA监测有显著性意义
核心结论
- Quidel MicroVue sC5b-9 Plus酶免疫分析法在筛查TA-TMA高风险患者中表现出良好的分析和临床性能。
研究设计与样本
- 收集骨髓移植患者及非TA-TMA风险患者的EDTA血浆样本,进行方法学验证(与另一实验室相关性、精密度、线性、溶血干扰)及回顾性临床数据分析。
主要发现
- 批内和日间精密度变异小于13%。
- 线性范围为80至1600 ng/mL。
- 溶血干扰至800 mg/dL未见干扰。
- 监测sC5b-9水平可检测提示TA-TMA的显著升高,便于及时进行eculizumab干预。
- sC5b-9变化2至3倍对TA-TMA患者监测具有显著性意义。
关键数值与推荐
- 批内和日间精密度变异小于13%。
- 线性范围为80至1600 ng/mL。
- 溶血干扰至800 mg/dL未见干扰。
- sC5b-9变化2至3倍对TA-TMA患者监测具有显著性意义。
临床怎么用
- 可用于筛查骨髓移植等TA-TMA高风险患者,通过监测sC5b-9水平变化辅助早期识别TA-TMA并及时启动eculizumab治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The complement membrane attack complex involves C5b-mediated assembly of C6-C9 polymers to form pores in cell membranes during complement activation. Inactive complexes can become soluble C5b-9 (sC5b-9) when they bind to Protein S. Elevated sC5b-9 levels are associated with increased risk of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a serious condition which can be improved with eculizumab therapy. Early detection of TA-TMA is essential for improving patient outcomes and optimizing the use of this costly treatment. We assessed the Quidel Microvue sC5b-9 Plus Enzyme Immunoassay on the Dynex-DS2 platform to screen for patients at risk of TA-TMA. METHODS: EDTA plasma samples were collected from bone marrow transplant (BMT) patients and others not at risk for TA-TMA. Assay validation included correlation with another laboratory, precision, linearity, and hemolysis interference. Additionally, clinical accuracy was assessed through retrospective patient data analyses. RESULTS: The assay showed acceptable intra- and interday precision, with less than 13 % variation. Linearity ranged from 80 to 1600 ng/mL, and there was no hemolysis interference up to 800 mg/dL. Clinical data revealed that monitoring sC5b-9 levels could detect significant increases indicative of TA-TMA, facilitating timely eculizumab intervention. Analytically, changes in sC5b-9 by 2- to 3-fold were significant for patient monitoring of TA-TMA. Lastly, a retrospective analysis on utility of the assay demonstrated effective utilization at our institution. CONCLUSION: The Quidel Microvue sC5b-9 Plus Enzyme Immunoassay demonstrated good analytical and clinical performance in screening patients with increased risk of TA-TMA.
引用
- Wilson RJ, Bhandari M, Dickerson JA, et al. Validation and performance of MicroVue sC5b-9 Plus ELISA on the Dynex DS2 platform. Clin Chim Acta. 2025. PMID: 39788342. doi:10.1016/j.cca.2025.120127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。